Multiple studies’ data support the use of Veracyte’s genomic classifiers to improve the diagnosis of lung cancer and idiopathic pulmonary fibrosis (IPF), the company reports. The data will be presented at the American Thoracic Society (ATS) 2017 International Conference, May 19-21 in Washington, D.C.

Two poster presentations will highlight data from studies supporting the clinical use of Percepta Bronchial Genomic Classifier to improve the safety and accuracy of lung cancer screening and diagnosis by resolving inconclusive bronchoscopy results in patients being evaluated for suspicious lung nodules or lesions.

Four other presentations will feature data on the clinical performance and utility of the Envisia Genomic Classifier, as well as the clinical need for the genomic test to resolve IPF-related challenges. Envisia was designed to improve diagnosis of IPF without the need for additional, costly and invasive procedures. Envisia was launched by Veracyte in late 2016.

The six presentations are:

• Sunday, May 21 (9:15 to 9:45 a.m.) – “Alterations in Bronchial Airway MicroRNA Expression as a Diagnostic Biomarker for Lung Cancer” (Abstract #1248)
• Sunday, May 21 (11:15 a.m. to 1 p.m.) – “A Bronchial Airway Gene Expression Signature Associated with Adenocarcinoma vs. Squamous Cell Lung Cancer” (Abstract #2372)
• Monday, May 22 (11:15 a.m. to 1 p.m.) – “Cohort Comparison Between Transbronchial Cryobiopsy and Surgical Lung Biopsy (SLB) in Patients Undergoing a Workup for Interstitial Lung Disease (ILD) from a Multicenter, Prospective Trial” (Abstract #3464)
• Monday, May 22 (11:15 a.m. to 1 p.m.) – “A Concordant Usual Interstitial (UIP) Diagnosis from Surgical Lung Biopsies (SLBs) Remains a Challenge for Patients with Interstitial Lung Disease (ILD)” (Abstract #3463)
• Tuesday, May 23 (2:15 to 3 p.m.) – “Prospective Validation of a Molecular Test for Usual Interstitial Pneumonia in Transbronchial Biopsies” (Abstract #6792)
• Tuesday, May 23 (2:15 to 3 p.m.) – “Analytical Performance of Envisia: a Genomic Classifier for Usual Interstitial Pneumonia Pattern” (Abstract #6784)

Both tests work by detecting genomic changes in the airways.

“Our Percepta and Envisia tests address real clinical needs by reducing the number of patients who must undergo risky, costly invasive procedures to resolve diagnostic uncertainty in lung cancer and IPF, respectively,” Bonnie Anderson, Veracyte’s CEO and chairman, said in a press release. “The data that will be presented at ATS reflect our strong commitment to building the clinical evidence necessary to drive adoption and reimbursement of these novel genomic classifiers, so that more patients and medical professionals can benefit from them.”